On 7, Professor Sheng Jindong from Tianjin Cancer Hospital presented oral results on the efficacy and safety of sacituzumab tirumotecan (sac-TMT) monotherapy for locally advanced or metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback